The transaction is designed to support Charlotte's Web's anticipated participation in the Centers for Medicare & Medicaid Innovation (CMMI) Medicare pilot program, alongside ongoing advancements in its FDA Phase 2 clinical trial program. The CEO of Charlotte's Web, Bill Morachnick, emphasized that this transaction not only simplifies the company's capital structure but also reflects strong support for its strategic direction. The additional capital will provide greater flexibility for the company to pursue its operational priorities.
The Board of Directors has evaluated the transaction in light of the company's current financial position and strategic priorities, concluding that the conversion of the debenture is consistent with market values and will eliminate the largest outstanding liability. The transaction is subject to shareholder approval, which will be sought at the upcoming annual general and special meeting scheduled for May 28, 2026. Upon completion, BAT is expected to hold approximately 40% of the company's common shares, significantly increasing its stake and influence in Charlotte's Web. This move is seen as a pivotal step in the company's ongoing efforts to enhance its financial stability and operational capabilities.
